C. diff Risk


Oral Bioavailability


Approximate Cost


2 g IV every 8 hr for severe infections

General Information

Unacceptable Uses

  • Patients with a PCN allergy when a cephalosporin option with low/no risk of cross-reactivity exists

Common Usage

Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent

Nebulized form used in cystic fibrosis patients

Empiric therapy for febrile neutropenia when severe penicillin allergy exists. Should be used in combination with a gram positive agent.

Drug Monitoring


  • SCr

  • Monitor liver enzymes


  • Hypersensitivity

  • Diarrhea

  • Phlebitis at injection site

Adverse Effects

  •  Elevated liver enzymes

  •  Eosinophilia

  •  Phlebitis at injection site

  •  Rash/allergy

  • Phlebitis at injection site

Major Interactions

No significant interactions.

Additional Information

Has no gram positive or anaerobic coverage


Antimicrobial class: Monobactam

Pregnancy category: B

Average serum half life: 2 hours

Biliary penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic